The real-life efficacy of early antiviral therapies in cancer patients with COVID-19 is largely uncharacterized. From these unresolved issues, it is therefore necessary to fill these knowledge gaps by assessing the efficacy and safety of these therapies in combination with anti-cancer therapies.

Inclusion Criteria:

1. Patients ≥ 18 years diagnosed with and/or treated for solid tumors at the department of Oncologia of the Fondazione IRCCS Policlinico San Matteo
2. Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document
3. Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

Exclusion Criteria:

• Patients who are unable to understand informed consent document

Patients with solid tumors on active treatment who have COVID-19 infection and receive an early therapy are eligible.

Patients admitted from January 2022 to December 2023 are candidate for the study. At the closure of the enrollment, we plan a further follow-up of 12 months.